by Brenda Baletti, Ph.D., Childrens Health Defense:

French scientist Hélène Banoun, Ph.D., author of the preprint study that analyzed outcomes from the 2023-2024 RSV immunization campaign in four countries, found a “significant increase in mortality” among newborns between 2 and 6 days of age in France. Banoun’s findings suggest that antibody-dependant enhancement may be to blame.